The markets opened flat with the Dow rising 19 points to 17,824 as Federal Reserve chair Janet Yellen testified on monetary policy before the Senate Banking Committee. Nasdaq added 4 points to 4,842.
On the upside
The New York Department of Health granted conditional approval to Rosetta Genomics' (Nasdaq: ROSG) multiple fluorescence in situ hybridization tests for detection of amplifications or rearrangements of DNA in hematologic cancers.
ChromoDex (Nasdaq: CDXC) said that an anonymous report issued by a short seller yesterday was laden with misinformation and innuendo.
Activist investor Paul Singer's Elliott Associates purchased 2.20 million shares of Imperva (NYSE: IMPV).
On the downside
Werner Enterprises (Nasdaq: WERN) warned of lower second quarter earnings prompting a downgrade.
Immunomedics (Nasdaq: IMMU) named Michael R. Garone to replace Peter P. Pfreundschuh as chief financial officer.
Impax Laboratories (Nasdaq: IPXL) will pay approximately $586 million to acquire a portfolio of generic drugs from Teva Pharmaceuticals (NYSE: TEVA) and affiliates of Allergan (NYSE: AGN).
In the broad market, declining issues outpaced advancers by a margin of nearly 5 to 4 on the NYSE and by nearly 5 to 3 on Nasdaq. The broader S&P 500 added 2 points to 2,086. Bitcoin plunged $75 to $646.
